Thor Medical Launches Commercial Production of Lead-212 at AlphaOne Facility

Thor Medical ASA announced on July 31 that commercial production has commenced at its industrial-scale AlphaOne production facility located in the Herøya industrial park. The facility will produce lead-212 (Pb-212) and its precursors thorium-228 (Th-228) and radium-224 (Ra-224) to support demand related to radiopharmaceuticals and targeted cancer radiotherapy.

According to the company, Thor Medical has signed supply agreements with multiple types of customers across the radiopharmaceutical value chain, including startup biotechnology companies, contract development and manufacturing organizations (CDMOs), and global pharmaceutical companies. The company expects the AlphaOne facility to deliver its first products to customers in August 2026.

The AlphaOne facility is based on the natural decay of thorium-232 (Th-232) as its raw material foundation, with plans to progressively ramp up production capacity and reach 21,000 patient dose equivalents within three years. Thor Medical CEO Jasper Kurth stated that stable access to medical isotopes is of significant importance for advancing innovative targeted cancer therapies into clinical application, and that AlphaOne will provide a scalable production platform to meet growing global demand.

Since 2024, Thor Medical has validated its proprietary production platform through pilot production and customer deliveries, and has built AlphaOne as an industrial-scale facility. The facility completed mechanical construction in April this year, followed by commissioning. During the commissioning phase, production systems, equipment, and process performance underwent systematic testing and validation to confirm that the facility can operate safely, reliably, and stably in accordance with design specifications.

Thor Medical stated that its production process applies advanced separation technology to natural thorium, requiring no irradiation process and no reliance on nuclear reactors, and can be used to supply high-purity radioactive isotopes.